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Unfortunately, no prospectively validated, facile, accepted AHF risk instruments for use in the ED setting exist (8) (9) (10) (11) (12) . Risk scores derived from administrative data show promise, but their lack of external prospective validation or difficulty of use has limited their uptake (13) (14) (15) (16) . Even the creation of risk instruments in the ED setting is difficult. Because most patients are admitted, separating the influence of hospitalization on the prognostic trajectory of patients is difficult (12) . This limits the applicability of hospital-based AHF risk scores to the ED setting.
Emergency physicians' low tolerance of risk compounds the problem: survey work suggests that significant adverse events cannot exceed 1% (17) . Thus, identification of low-risk patients with AHF in the ED setting is a major unmet clinical need.
Myocardial injury, as measured by troponin release, is a marker of higher risk (18) (19) (20) (21) . A previous RELAX-AHF (Serelaxin, Recombinant Human
Relaxin-2, for Treatment of Acute Heart Failure) analysis demonstrated that baseline, peak, and peak change in high-sensitivity troponin T (hsTnT) was associated with worse outcomes (22) . Similar to acute coronary syndrome (ACS), higher levels of troponin are associated with worse outcomes in AHF (18) (19) (20) 23 Results from both univariate and multivariate analyses are presented, using predictor variables of clinical importance and consistent with past RELAX-AHF analyses (24, 26) . See Online Table 1 for a list of the covariates, which included, among other variables, age, sex, blood pressure, treatment, NT-proBNP, creatinine, and blood urea nitrogen. Online Table 1 presents the adjustment variables included in the multivariate models. Of note, NT-proBNP was modeled as a continuous variable. Linear regression models were created for noncategorical endpoints,
and Cox models for time-to-event endpoints. (Proportional hazards assumptions were checked and satisfied.) These models are conservative, as all clinical variables of interest were included. However, given the concern for overspecification, additional models with greater efficiency were created using backward elimination (Online Table 3 ). Cross validated C-indexes were calculated to allow model comparison.
Statistical significance was set at the 0.05 level.
When no events were observed in a patient subgroup of interest, score test methods were used to report p values and CIs. In all other cases, Wald procedures were used. .014 mg/l). Table 1 shows baseline characteristics stratified by hsTnT #0.014 mg/l. Age was similar between the groups, with an average age of 71 years in the low-hsTnT group. Fewer patients in the low-hsTnT group were male or had reduced ejection fractions.
There were no differences in baseline vital signs, with the exception of heart rate being 3 beats/min faster in the low-hsTnT group. Of note, there were no differences in history of ischemic heart disease, New York Heart Association class, HF hospitalization in the past year, or signs and symptoms of HF. With the exception of oral loop diuretic agents and betablockers, there were no other differences in terms of baseline medications. Fewer patients had histories of diabetes, but no other significant differences in comorbidities were observed. In terms of laboratory values, low-hsTnT patients had better renal function and lower NT-proBNP levels (median 3,422 vs. 5,313
ng/l in the elevated-hsTnT group) (Online Table 2 lists a comprehensive comparison of baseline characteristics). Table 3 ). Only 1 patient with low hsTnT died of a non-CV cause. thus, the threshold value of hsTnT to define low risk is unknown. A less sensitive assay was used in ASCEND-HF (27) . Unlike the RELAX-AHF trial, patients were enrolled up to 24 h after presentation. (13) . Although observation unit pathways exist, they are underused and lack the supportive evidence from a robust randomized controlled trial (11) . In fact, American Heart Association and American Values are hazard ratio (95% confidence interval). *Independent variable is dichotomized (low vs. elevated) troponin. †Adjustment variables are as listed in Online Table 1 and treatment. ‡Troponin level by treatment interaction term is added to multivariate model. §Continuous endpoint: mean difference (95% CI) reported as effect. ||Time-to-event endpoint: HR (95% CI) reported as effect. ¶There were no cardiovascular death events in the low-troponin group. This caused the Wald chi-square test to be unreliable, so much so that SAS could not produce an upper confidence limit. Upper confidence limits and p values were produced using score-test methods instead. #No patient scored 0 on BMDEX (BMDEX ¼ baseline dyspnea on exertion-imputed) at level 0 had a CVDT180 event (CVDT 180 ¼ CV death through day 180). BMDEX ¼ 0 and BMDEX ¼ 1 are grouped together as the reference level. **Interaction p value was calculated using the score-test chi-square statistic with 1 degree of freedom. † †There was insufficient information in the data to estimate the interaction p value. ‡ ‡Mean (95% CI) is presented for continuous outcomes, and n (%) is presented for time-to-event outcomes.
CV ¼ cardiovascular; HF ¼ heart failure. Values are hazard ratio (95% confidence interval). *Independent variable is dichotomized (low vs. elevated) troponin. †Continuous endpoint: mean difference (95% CI) reported as effect. ‡Time-to-event endpoint: HR (95% CI) reported as effect. §Categorical endpoint: OR (95% CI) reported as effect. ||Mean (95% CI) is presented for continuous outcome, and n (%) is presented for binary and time-to-event outcomes.
AUC ¼ area under the curve; IV ¼ intravenous; OR ¼ odds ratio; VAS ¼ visual analogue scale; WHF ¼ worsening heart failure; other abbreviations as in Table 2 .
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College of Cardiology HF guidelines focus on management once hospitalized, highlighting the paucity of ED-based evidence (29) .
In the setting of low-risk identification, these find- However, it has been studied primarily as a marker of high risk; whether absence of troponin release is associated with low risk has not been previously well studied. In this post hoc study, baseline hsTnT #99th percentile identified patients at very low risk for 180-day CV mortality. 
